Literature DB >> 23955962

The crude extract of Corni Fructus inhibits the migration and invasion of U-2 OS human osteosarcoma cells through the inhibition of matrix metalloproteinase-2/-9 by MAPK signaling.

Ching-Lung Liao1, Ju-Hwa Lin, Jin-Cherng Lien, Shu-Chun Hsu, Fu-Shin Chueh, Chien-Chih Yu, Ping-Ping Wu, Yi-Ping Huang, Jaung-Geng Lin, Jing-Gung Chung.   

Abstract

Osteosarcoma is the most common primary malignancy of the bone cancers. In the Chinese population, the crude extract of Corni Fructus (CECF) has been used as Traditional Chinese medicine to treat several different diseases for hundreds of years. In the present study, effects of CECF on inhibition of migration and invasion in U-2 OS human osteosarcoma cells were examined. CECF significantly inhibited migration and invasion of U-2 OS human osteosarcoma cells. We also found that CECF inhibited activities of matrix metalloproteinases-2 (MMP-2) and matrix metalloproteinases-9 (MMP-9). CECF decreased protein levels of FAK, PKC, SOS1, MKK7, MEKK3, GRB2, NF-κB p65, COX-2, HIF-1α, PI3K, Rho A, ROCK-1, IRE-1α, p-JNK1/2, p-ERK1/2, p-p38, Ras, p-PERK, MMP-2, MMP-9, and VEGF in U-2 OS cells. Results of this study indicate that CECF may have potential as a novel anticancer agent for the treatment of osteosarcoma by inhibiting migration and invasion of cancer cells.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  U-2 OS human osteosarcoma cells; crude extract of Corni Fructus (CECF); invasion; migration

Mesh:

Substances:

Year:  2013        PMID: 23955962     DOI: 10.1002/tox.21894

Source DB:  PubMed          Journal:  Environ Toxicol        ISSN: 1520-4081            Impact factor:   4.119


  11 in total

1.  Knockdown of Aurora-B alters osteosarcoma cell malignant phenotype via decreasing phosphorylation of VCP and NF-κB signaling.

Authors:  Jian Ying He; Wei Hong Xi; Liang Bo Zhu; Xin Hua Long; Xuan Yin Chen; Jia Min Liu; Qin Feng Luo; Xiao Ping Zhu; Zhi Li Liu
Journal:  Tumour Biol       Date:  2015-01-21

2.  Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway.

Authors:  Liang Bo Zhu; Jian Jiang; Xiao Ping Zhu; Tao Fang Wang; Xuan Yin Chen; Qin Feng Luo; Yong Shu; Zhi Li Liu; Shan Hu Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Reinforcement of Sorafenib Anti-osteosarcoma Effect by Amentoflavone Is Associated With the Induction of Apoptosis and Inactivation of ERK/NF-κB.

Authors:  Chun-Min Su; Chi-Huan Li; Meng-Chu Huang; Po-Fu Yueh; Fei-Ting Hsu; Rong-Fong Lin; Li-Cho Hsu
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

4.  Recent highlights of experimental research for inhibiting tumor growth by using Chinese medicine.

Authors:  Xi-ran He; Shu-yan Han; Ping-ping Li
Journal:  Chin J Integr Med       Date:  2015-11-03       Impact factor: 1.978

5.  Inhibition of hypoxia inducible factor-1α downregulates the expression of epithelial to mesenchymal transition early marker proteins without undermining cell survival in hypoxic lens epithelial cells.

Authors:  Patrick R Cammarata; Sudha Neelam; Morgan M Brooks
Journal:  Mol Vis       Date:  2015-09-01       Impact factor: 2.367

6.  Punicalagin inhibited proliferation, invasion and angiogenesis of osteosarcoma through suppression of NF‑κB signaling.

Authors:  Tao Huang; Xin Zhang; Haipeng Wang
Journal:  Mol Med Rep       Date:  2020-07-06       Impact factor: 2.952

7.  Monocyte Chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma.

Authors:  Ju-Fang Liu; Po-Chun Chen; Tsung-Ming Chang; Chun-Han Hou
Journal:  J Exp Clin Cancer Res       Date:  2020-11-23

8.  An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9.

Authors:  Qiang Ding; Yujia Xia; Shuping Ding; Panpan Lu; Liang Sun; Mei Liu
Journal:  Oncotarget       Date:  2016-03-22

9.  Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression.

Authors:  Hsin-Lin Cheng; Ming-Ju Hsieh; Jia-Sin Yang; Chiao-Wen Lin; Ko-Haung Lue; Ko-Hsiu Lu; Shun-Fa Yang
Journal:  Oncotarget       Date:  2016-06-07

10.  Effective Material Basis and Mechanism Analysis of Compound Banmao Capsule against Tumors Using Integrative Network Pharmacology and Molecular Docking.

Authors:  Tian-Mu He; Jing-Xian Liu; Can-Can Duan; Xiao-Fei Li; Jian-Yong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.